Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing

View source ↗

Summary

EMA restricts the use of Lemtrada (alemtuzumab) while ongoing review is concluded, limiting certain patient groups and requiring adherence to updated safety mea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)